Marine Gross-Goupil

5PUBLICATIONS
29CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Epidemiological modellingPharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|May 26, 2026
Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study.

|Sep 20, 2024
Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial.

Robert J Motzer, Axel Bex, Paul Russo

|May 11, 2024
How Immunotherapy Has Redefined the Treatment Paradigm of Metastatic or Locally Advanced Muscle-Invasive Urothelial Bladder Carcinoma.

Mathieu Larroquette, Félix Lefort, Charlotte Domblides

|Dec 13, 2023
Clustering of prostate cancer healthcare pathways in the French National Healthcare database.

Roméo Baulain, Jérémy Jové, Dunia Sakr

|Aug 19, 2022
Abiraterone acetate versus docetaxel for metastatic castration-resistant prostate cancer: a cohort study within the French nationwide claims database.

Nicolas H Thurin, Magali Rouyer, Jérémy Jové

Pageof 1

Frequent Collaborators

2 joint publications

Nicolas H Thurin

2 joint publications

Magali Rouyer

2 joint publications

Cécile Droz-Perroteau

2 joint publications

Patrick Blin